

## MLSC Company Formation Awards

Company or Organization Name	Name	Phone Number	Project Description	Funding Amount Approved
Jasper Clinical R&D	Edward Antal	(269) 833-1317	A new business, Jasper Clinical R&D, comprises a recognized, world-class, clinical research unit that would replace the clinical research unit scheduled for closure under the Pfizer Kalamazoo site plan, and a drug development consultation service focused on early development that will support the core function of the clinical research unit. This proposal extending over three years includes 46 positions with a combined annual salary of \$3.1 million. Clinical staff represent both Pfizer and Bronson Hospital contract employees, while the drug development consultation service staff consists of four Pfizer senior	\$175,000
KalXPro (Proteos)	Robert Heinrikson	(269) 598-1950	This is a contract research organization for provision of high quality proteins and peptides, and analytical validation of the products. Customers will include large pharmaceutical companies, start-up biotech companies, and university scientists who do not have access to this level of expertise. Key personnel are currently senior scientists at Pfizer.	\$200,000
Trilithon Pharma, LLC	Steve Sensoli	(734) 637-3490	Seeks to establish a center of excellence for development and marketing of cardiovascular products in Kalamazoo. The company plans to use facilities within the Southwest Michigan Innovation Center and at Western Michigan University. During its first year, Trilithon will employ at least 10 senior pharmaceutical and administrative professionals, invest \$8 million in product development and generate an annual payroll of more than \$1.6 million.	\$200,000
CeeTox	James McKim	(269) 324-2017	CeeTox Labs will be established as a contract research organization with two objectives. The first is to provide novel and state-of-the-art in-vitro toxicity testing to the chemical and pharmaceutical industry. The second is the development and marketing of novel biomarkers of specific types of toxicity. The data generated will have applications in the pharmaceutical and chemical industries in understanding the toxic liabilities of new chemical entities and building comparative databases with similar compounds.	\$200,000
Molecular Imaging Research Inc.	Wilbur Leopold	(734) 222-9900	Molecular Imaging, an Ann Arbor biotech company, will establish a wholly owned subsidiary, Molecular Imaging Research, to leverage MRx technology and the cancer research expertise of key Pfizer employees. It will operate as a fee-for-service facility to evaluate novel anti-tumor agents making use of molecular imaging technologies. Funding will be used to acquire necessary specialized equipment.	\$200,000
Kalexsyn	Robert Gadwood	(269) 833-1974	Kalexsyn, to be located in Kalamazoo, will provide high quality, contract medicinal chemistry services to pharma, biotech and other science-based companies as well as academic labs in Michigan. Requested funding, matched by company founders, will support Kalexsyn in its first three months of operation. Initial employment will be 10-20 chemists with anticipated growth to 40 employees by the third year.	\$192,200
STATPROBE	John Freshley	(734) 769-5000	Statprobe will build on its position as Michigan's largest contract research organization to establish a Kalamazoo office over a six-month period, recruiting senior level personnel from Kalamazoo. The company's initial plan is to promote its CRO services to current and potential clients nationwide, identify potentially interested companies and determine needs and level of interest. They will seek clients interested in dedicated functional teams, and will also consider smaller projects.	\$200,000
AmphiBiotics, LLC	Steve Sensoli	(734) 637-3490	This company seeks to establish antimicrobial drug research, development and marketing capabilities in Kalamazoo. Plans include occupancy of lab and office space within the Southwest Michigan Innovation Center, employment of eight people within six months and a projected payroll of \$2 million. This seed funding will result in more than \$20 million of research spending in the first two years and up to 25 new jobs.	\$200,000
ADMETRx	Jay Goodwin	(269) 760-8881	This company will provide services for drug discovery and preclinical optimization of ADME/biopharmaceutical properties. The data will be used to provide structure-based property models to the customer in the form of interactive software to facilitate optimization.	\$200,000
DKb Technologies	Patricia Ruppel	(269) 806-5975	The mission of DKb is to increase the value of scientific data collection to enable innovation in R&D organizations. Funding will be used to acquire the hardware, software licensing and specialized IT infrastructure required to support this venture. Growth is targeted to 14 employees from the current two founders within two years. Research areas include gene expression, cognition testing, MRI image analysis and pharmacogenomics.	\$56,000
AbA Pharmaceuticals	Ake Elhammer	(269) 544-0458	The company intends to engineer an organism producing a known antifungal compound, a drug candidate owned by Pfizer, that requires extensive chemical modifications for activity, to instead produce the almost finished molecule. As a second goal, the intention is to prepare engineered organisms producing novel cyclic peptides. This will generate the potential for discovery of novel antifungal, as well as antibacterial, cancer and immunosuppressive drugs.	\$200,000